NED Axol Biosciences, NovalGen. Chairman Concinnity Genetics. Former President of AskBio Europe; CEO at Synpromics, Anatara Lifesciences and Ark Therapeutics. Founding leadership team NightStar Therapeutics. Honorary Professor, Edinburgh University.
Former Coordinator of the European Stem Cell Bank; Senior Research Fellow at Pfizer; Chief Science Officer of Stem Cell Sciences plc
Former Group Leader at King’s College London, Department of Medical and Molecular Genetics. Extensive expertise in gene editing and RNAi technology research.
Former Financial Controller and Company Secretary Acacia Pharma Group, Senior Audit Manager PwC.
Former CSO at Oxgene; Research management at Cellinta, Lonza, Novozymes. Extensive expertise in the gene therapy and gene editing sector.
Former VP People at Tropic Biosciences, former HR Leader at Horizon Discovery (now Reevity), and United Nations Environment Programme.
Former Research Fellow, University of Queensland
Former Director of Immunology, Owkin; Director, Oncology Cell Therapy, GSK; Senior Scientist, Horizon Discovery
Non-exec director and treasurer, ELRIG. Former Head of Immunology Services and R&D, Revvity
COO Ambrose Health (Fractional), Former CEO Enhanc3d Genomics, Oncology Chief of Staff, AstraZeneca
NED Axol Biosciences, NovalGen. Chairman Concinnity Genetics. Former President of AskBio Europe; CEO at Synpromics, Anatara Lifesciences and Ark Therapeutics. Founding leadership team NightStar Therapeutics. Honorary Professor, Edinburgh University.
Former Coordinator of the European Stem Cell Bank; Senior Research Fellow at Pfizer; Chief Science Officer of Stem Cell Sciences plc
Former Group Leader at King’s College London, Department of Medical and Molecular Genetics. Extensive expertise in gene editing and RNAi technology research.
Former Partner at the Boston Consulting Group, former COO at Cellectis. Chair Treefrog Therapeutics, Non-exec board member Gensight.
Former Financial Controller and Company Secretary Acacia Pharma Group, Senior Audit Manager PwC.
Former CSO at Oxgene; Research management at Cellinta, Lonza, Novozymes. Extensive expertise in the gene therapy and gene editing sector.
Former VP People at Tropic Biosciences, former HR Leader at Horizon Discovery (now Reevity), and United Nations Environment Programme.
Former Research Fellow, University of Queensland
Former Director of Immunology, Owkin; Director, Oncology Cell Therapy, GSK; Senior Scientist, Horizon Discovery
Non-exec director and treasurer, ELRIG. Former Head of Immunology Services and R&D, Revvity
CEO AviadoBio, Former SVP and CBO Novartis Gene Therapies. Board member Alliance of Regenerative Medicine.
CEO Tropic Biosciences. Experienced AgriTech entrepreneur and investor, who is deeply passionate about utilizing cutting-edge technologies in solving real world challenges.
Investor Director, Calculus Capital. Board member, MIP Discovery, Tagomics, Invizius. 20 years experience in life science investing. Founding team Klein-Edmonds Associates.
NED Axol Biosciences, NovalGen. Chairman Concinnity Genetics. Former President of AskBio Europe; CEO at Synpromics, Anatara Lifesciences and Ark Therapeutics. Founding leadership team NightStar Therapeutics. Honorary Professor, Edinburgh University.
Former Parter at Delin Ventures, Senior Director Eli Lilly, Head of Strategy UK & Ireland Merck Serono. Extensive experience across business development, company building and VC.
